Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. A commentary.
Although few objective data are available from which to derive strict and definitive guidelines for both staging of newly diagnosed patients and surveillance following treatment, rational recommendations can be offered that can minimize patient morbidity and costs.